Another study that analyzed Medicare Part B data from 2012 to 2015 found an increasing trend in the use of anti-VEGF therapies, particularly aflibercept.
← all excerpts
Real-World Research on Retinal Diseases Using Health Claims Database: A Narrative Review.
1
—
—